Emerald Health Therapeutics Expands Distribution of its SYNC 25 CBD Oil to Two More Canadian Provinces
July 10 2019 - 7:00AM
Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX:
EMHTF) has shipped 9,960 40-ml units of its SYNC 25 CBD oil to
Alberta and Saskatchewan. The Emerald-branded Indica-dominant CBD
oil offers consumers a smoke-free product alternative.
“CBD oil has become an increasingly popular
product on the market today, and our cannabis-derived SYNC 25 is an
example of the high-quality products that consumers can expect from
Emerald,” said Dr. Avtar Dhillon, President and Executive Chairman
of Emerald. “With our range of expertise in the research and
development of science-driven products, we will continue to expand
our product portfolio and meet consumer demand.”
SYNC 25 has been shipped to Alberta Gaming,
Liquor and Cannabis and to private retailers authorized by the
Saskatchewan Liquor and Gaming Authority. In May, Emerald shipped
6,000 40-ml units of SYNC 25 to the British Columbia Liquor
Distribution Branch.
About Emerald Health Therapeutics,
Inc.
Emerald Health Therapeutics, Inc. is a Canadian
licensed producer of cannabis products, with strategic initiatives
focused on differentiated, value-added product development for
medical and adult-use customers supported by novel intellectual
property, large-scale cultivation, extraction, and softgel
encapsulation, as well as unique marketing and distribution
channels. Its 50%-owned Pure Sunfarms operation in British Columbia
is in full production in its first 1.1 million square foot
greenhouse, with growing capacity of approximately 75,000 kg; a
second 1.1 million square foot greenhouse is planned to be in full
production by the end of 2020. Emerald’s two other wholly-owned
facilities in Québec, a high-quality indoor growing and processing
facility, and British Columbia, an organic greenhouse and outdoor
operation, are completing construction and are working toward final
permitting. Emerald has also contracted for approximately 1,200
acres of hemp annually in 2019 to 2022 with the objective of
extracting low-cost CBD. Its team is highly experienced in life
sciences, product development, large-scale agri-business, and
marketing.
Emerald is part of the Emerald Health group,
which represents a broad array of companies focused on developing
pharmaceutical, botanical, and nutraceutical products aimed at
providing wellness and medical benefits by interacting with the
human body’s endocannabinoid system.
For further information about Emerald Health Therapeutics.
Please visit www.emeraldhealth.ca or contact: Rob Hill, Chief
Financial Officer (800) 757 3536 Ext. #5
Emerald Investor Relations (800) 757 3536 Ext.
#5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include production and processing capacity of various facilities;
expansion of facilities; anticipated production costs; acquisition
of hemp; development and sale of products; and expansion of product
portfolio.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, failure to obtain regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labour;
demand for products; as well as the risk factors described in the
Company’s annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Sep 2023 to Sep 2024